Drug Trial Radar · NCT00691002
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,245
Actual
Start
May 2008
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous areas (= double-blind phase). Furthermore, the safety and efficacy will be evaluated for up to 60 weeks treatment as required of calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ointment in psoriasis vulgaris on the face and intertriginous areas (= open-label phase).
Conditions
- Psoriasis Vulgaris
Interventions
Calcipotriol plus hydrocortisone (LEO 80190)Drug
Once daily application
LEO 80190 VehicleDrug
HydrocortisoneDrug
CalcipotriolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind PhaseTime frame: At Week 8 (end of treatment for double-blind phase)
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Croatia - managed by CRO
Zagreb, Croatia
Macedonia - managed by CRO
Zagreb, Croatia
Slovenia - managed by CRO
Zagreb, Croatia
Department of Dermatology and Allergy, University of Bonn
Bonn, Germany
Czech Republic - managed by CRO
Warsaw, Poland
Hungary - managed by CRO
Warsaw, Poland
Latvia - managed by CRO
Warsaw, Poland
Poland - managed by CRO
Warsaw, Poland
Belgium - managed by CRO
Warsaw, Poland
The Netherlands - managed by CRO
Warsaw, Poland
Serbia - managed by CRO
New Belgrade, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.